Cannabidiol

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Cannabidiol
   1. Pharmacist Assessment Report
   2. Cannabidiol: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Cytotoxicity
   8. Safety Considerations
   9. Disclaimer

---

Pharmacist Assessment Report

Cannabidiol: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Cannabidiol, so there is currently no new predicted indication. The drug’s recorded uses are listed below.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	7
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
lennox gastaut syndrome	licence in another country
myoclonic epilepsies	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
cutis verticis gyrata
developmental and epileptic encephalopathy
dravet syndrome
early myoclonic encephalopathy
lennox-gastaut syndrome

Australia Market Information

Licence	Product	Dosage form	Status
12467E	Epidyolex	Oral liquid 100 mg per mL, 100 mL	Valid

Cytotoxicity

Not applicable. Cannabidiol is not an antineoplastic drug.

Safety Considerations

• Drug Interactions: 100 interactions were identified; the first 20 retrieved are summarised here. Most are Moderate or Minor.
  • Moderate: acarbose, pioglitazone, bupropion, morphine (including liposomal), chenodeoxycholic acid, clotrimazole, dronabinol, levofloxacin, metoclopramide, minocycline, nabilone, naltrexone, nicotinamide, opium.
  • Minor: aprepitant, clarithromycin, esomeprazole, lansoprazole, omeprazole.
  • Combined use with other cannabinoids (dronabinol, nabilone) and opioids warrants particular attention because of possible additive central nervous system effects.

Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---